CAS: 66778-36-7; 4-Methoxy-N-(2-(2-(1-Methylpiperidin-2-yl)Ethyl)Phenyl)Benzamide

该化合物是一种主要用作抗心律剂的药物化合物,属于钠管阻塞剂,在心脏行动潜力的脱冰阶段抑制钠离子的流入,有助于稳定心脏膜,恢复心律不全的病人的正常节奏.乙酰胺的特点是其化学结构,包括一条管状环和芳香味,有助于其药理特性.该物质通常以受控方式进行,因为其潜在的副作用,其中可能包括先天性心律不齐,特别是在有心脏病症的病人中.在临床环境中对安眠素的功效和安全情况进行了评估,对于保健提供者来说,重要的是要密切监测病人的任何不良反应.与许多抗心律药物一样,对丙胺的治疗使用需要仔细考虑病人的总体健康状况和潜在的药物相互作用.

结构式图片

物理性质

MSDS等安全信息

欧盟法规

C&L通报

上下游产品

N-Desmethylencainide 87085-10-7
N-[2-[1-Hydroxy-2-(1-Methyl-3,6-Dihydro-2H-Pyridin-6-yl)Ethyl]Phenyl]-4-Methoxybenzamide 153707-65-4
Methyl 2-[(4-Methoxybenzoyl)Amino]Benzoate 37619-28-6
4-Methoxy-N-<2-(2-Pyridinylacetyl)Phenyl>Benzamide 87165-92-2
2-(邻-氨基苯乙基)-1-甲基哌啶 2-(2-Aminophenethyl)-1-Methylpiperidine 37611-80-6
4-甲氧基-N-(2-(1-羟基-2-(2-吡啶基)乙基)苯基)苯甲酰胺 4-Methoxy-N-<2-<1-Hydroxy-2-(2-Pyridinyl)Ethyl>Phenyl>Benzamide 153707-63-2

合成工艺路线路线简述

    📜碳酸甲丙酯置于palladium On Activated Charcoal 盐酸,Sodium Tetrahydroborate,氢气,Lithium Diisopropyl Amide体系中,用 四氢呋喃,甲醇,乙醇,水,乙腈 作为反应溶剂,化学反应 22.25H,反应生成 (+/-)-4-甲氧基-N-[2-[2-(1-甲基-2-哌啶基)乙基]苯基]苯甲酰胺
    参考文献:活化的甲基吡啶与邻氨基苯甲酸酯和邻硝基苯甲醛的缩合反应:抗心律不齐药物恩卡尼特的合成方法改进
    标题:活化的甲基吡啶与邻氨基苯甲酸酯和邻硝基苯甲醛的缩合反应:抗心律不齐药物恩卡尼特的合成方法改进
    摘要:提出了两种新的和改进的抗心律不齐药物encainide 1的合成方法.第一种方法基于2-吡啶甲基锂与邻氨基苯甲酸甲酯3的对-异戊酰胺的缩合,然后进行一系列催化氢化和甲基化.第二种途径依赖于n-甲基吡啶甲基硫酸甲酯和邻硝基苯甲醛之间特别容易的缩合反应,以高收率生产醇17C,该醇通过新颖的脱水方法转化为烯烃18C,然后通过催化加氢转化为最终分子在铂上,然后进行酰化反应.
    DOI:10.1002/jhet.5570300321

    海关参考信息

    专利信息


    专利号:US-10925977-B2
    优先权日:2006-10-05
    标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
    发明人：YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S
    权利人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S; CEIL POINT LLC; UNIV TEXAS
    摘要:Novel methods of synthesis of chelator-targeting ligand conjugates, compositions comprising such conjugates, and therapeutic and diagnostic applications of such conjugates are disclosed. The compositions include chelator-targeting ligand conjugates optionally chelated to one or more metal ions. Methods of synthesizing these compositions in high purity are also presented. Also disclosed are methods of imaging, treating and diagnosing disease in a subject using these novel compositions, such as methods of imaging a tumor within a subject and methods of diagnosing myocardial ischemia.

    专利号:US-10814013-B2
    优先权日:2006-10-05
    标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications

    专利号:WO-2009035652-A1
    优先权日:2007-09-13
    标 题 :Synthesis of deuterated catechols and benzo[d][1,3] dioxoles and derivatives thereof

    专利号:AU-2007308022-A2
    优先权日:2006-10-05
    标题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications

    专利号:AU-2007308022-A1
    优先权日:2006-10-05
    标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications

    专利号:US-2008107598-A1
    优先权日:2006-10-05
    标 题:Efficient Synthesis of Chelators for Nuclear Imaging and Radiotherapy: Compositions and Applications

    其他信息查阅

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    实用工具

    ⚠️全国化工行业净网倡议书
    📋制造商识别码
    📖 海关编码查询
    📝MSDS生成器

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, Arensberg D, Baker A, Friedman L, Greene HL, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991 Mar 21;324(12):781-8. Review. Review. Review. doi: 10.2165/11318030-000000000-00000. Review. Review. Review.

    合成参考文献


    摘要:Annals of Emergency Medicine., 21(998), 1992 []
    参考文献:10.1007/s11920-004-0065-1
    摘要:Jiang W, Krishnan RR. Should selective serotonin reuptake inhibitors be prescribed to all patients with ischemic heart disease Curr Psychiatry Rep. 2004 Jun;6(3):202–9. doi: 10.1007/s11920-004-0065-1.
    参考文献:10.1007/s00392-004-0067-3
    摘要:Haas NA, Plumpton K, Justo R, Jalali H, Pohlner P. Postoperative junctional ectopic tachycardia (JET). Clinical Research in Cardiology. 2004 May;93(5):371–80. doi: 10.1007/s00392-004-0067-3.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知